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ABSTRACT
Introduction Over half of those hepatitis C virus (HCV)/
HIV coinfected live in low- income and middle- income 
countries, and many remain undiagnosed or untreated. 
In 2016, Médecins Sans Frontières (MSF) established a 
direct- acting antiviral (DAA) treatment programme for 
people HCV/HIV coinfected in Myanmar. The purpose 
of our study was to evaluate the real- world cost and 
cost- effectiveness of this programme, and potential cost- 
effectiveness if implemented by the Ministry of Health 
(MoH).
Methods Costs (patient- level microcosting) and treatment 
outcomes were collected from the MSF prospective cohort 
study in Dawei, Myanmar. A Markov model was used to 
assess cost- effectiveness of the programme compared 
with no HCV treatment from a health provider perspective. 
Estimated lifetime and healthcare costs (in 2017 US$) 
and health outcomes (in disability- adjusted life- years 
(DALYs)) were simulated to calculate the incremental cost- 
effectiveness ratio (ICER), compared with a willingness- 
to- pay threshold of per capita Gross Domestic Product in 
Myanmar ($1250). We evaluated cost- effectiveness with 
updated quality- assured generic DAA prices and potential 
cost- effectiveness of a proposed simplified treatment 
protocol with updated DAA prices if implemented by the MoH.
Results From November 2016 to October 2017, 122 
with HIV/HCV- coinfected patients were treated with DAAs 
(46% with cirrhosis), 96% (n=117) achieved sustained 
virological response. Mean treatment costs were $1229 
(without cirrhosis) and $1971 (with cirrhosis), with DAA 
drugs being the largest contributor to cost. Compared 
with no treatment, the program was cost- effective (ICER 
$634/DALY averted); more so with updated prices for 
quality- assured generic DAAs (ICER $488/DALY averted). A 
simplified treatment protocol delivered by the MoH could 
be cost- effective if associated with similar outcomes (ICER 
$316/DALY averted).
Conclusions Using MSF programme data, the DAA 
treatment programme for HCV among HIV- coinfected 
individuals is cost- effective in Myanmar, and even more 
so with updated DAA prices. A simplified treatment 
protocol could enhance cost- effectiveness if further rollout 
demonstrates it is not associated with worse treatment 
outcomes.
INTRODUCTION
Among people living with hepatitis C virus 
(HCV) infection, coinfection with HIV can 
lead to accelerated liver cirrhosis, liver cancer 
and death compared with those with HCV 
monoinfection.1–3 Globally, an estimated 
6.2% of people living with HIV show serolog-
ical evidence of HCV antibody (2.3 million 
individuals), the majority residing in low/
Key questions
What is already known?
 ► Estimates show that implementing hepatitis C virus 
(HCV) screening and treatment programmes with 
generic direct- acting antivirals (DAAs) would be 
cost- saving within a 10- year period.
 ► HCV treatment is likely cost- effective in low/middle- 
income country (LMIC) settings where DAAs are 
available at low costs.
What are the new findings?
 ► Using Médecins Sans Frontières programme data, 
we found that compared with no treatment, HCV 
treatment with quality- assured DAA among HIV- 
coinfected individuals is cost- effective in Myanmar.
 ► Access to affordable, quality- assured generic DAAs 
improved cost- effectiveness.
 ► A simplified treatment protocol delivered by the 
Ministry of Health could be highly cost- effective 
among HIV/HCV- coinfected individuals if combined 
with an HCV screening programme.
What do the new findings imply?
 ► A simplified treatment protocol could enhance cost- 
effectiveness if not associated with worse treatment 
outcomes.
 ► National HCV programmes in Myanmar and similar 
LMIC settings should no longer consider DAA cost 
a barrier, but rather consider these data along with 
simplified models of care as a means to cure people 
with HCV infection and progress towards WHO HCV 
elimination goals.
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middle- income countries (LMICs).4 In Myanmar, an esti-
mated 5.3% of the 222 000 HIV- infected individuals are 
HCV- seropositive,5–7 but in the rural Southern township 
of Dawei, HCV seroprevalence rises to 8% among people 
living with HIV (data unpublished), and as high as 23% 
among male HIV- infected fishermen.8
Promisingly, HCV treatment with new direct- acting 
antivirals (DAAs) is highly effective among HCV/
HIV- coinfected individuals (>90% cure rate).9 Yet the 
previous high cost of DAAs restricted many individuals 
in LMIC settings from accessing treatment in these 
highest burdened areas.10 Few studies have evaluated 
the cost- effectiveness of HCV treatment in LMIC settings 
where healthcare management of liver disease and costs 
of providing DAA treatment differ dramatically from 
high- income countries. Existing evaluations are limited 
to theoretical analyses of DAA- containing regimens for 
HCV monoinfection in Egypt, India, Pakistan and Thai-
land; and have not evaluated real- world programme 
implementation costs or cost- effectiveness.11–14 Evalu-
ating real- world HCV treatment programmes in low- 
income settings is critical to designing and implementing 
cost- effective HCV treatment programmes to achieve 
the global HCV elimination targets set by the WHO as it 
provides real data of current programmes which allow a 
better understanding of which components are driving 
cost and where cost- savings can be made.15
In 2016, Médecins sans Frontières (MSF) began a 
UNITAID- funded HCV treatment programme within an 
HIV cohort in Dawei, Myanmar using interferon (IFN)- 
free DAA- based regimens, and in 2018, obtained updated 
prices for quality- assured generic DAAs.16 With program-
matic experience treating HCV/HIV- coinfected patients 
in Dawei, MSF subsequently proposed a simplified HCV 
treatment protocol as a potential HCV model of care that 
aligns with the 2017 Myanmar Ministry of Health (MoH) 
National Hepatitis Guidelines.
The purpose of this primary research, performed 
in collaboration with MSF, was to evaluate the cost of 
providing DAA treatment in the MSF programme and 
assess the cost- effectiveness of the programme compared 
with no treatment among HCV/HIV- coinfected patients 
in Myanmar. Additionally, we use these data to evaluate 
the potential cost- effectiveness of HCV treatment using 
generic DAAs and a simplified treatment protocol as 
proposed by MSF to the Myanmar MoH. To our knowl-
edge, this is the first study to conduct a cost and cost- 
effectiveness analysis of a real- world HCV treatment 
programme for HIV- infected individuals in an LMIC.
METHODS
Setting and model of care
The MSF- Dawei HIV clinic was established in 2004, 
targeting patients in Dawei and the entire Thanintharyi 
division in Southern Myanmar. In 2014, MSF began 
screening all HIV- positive patients attending the MSF- 
Dawei HIV clinic (87% of HIV- positive patients in the 
region) for HCV, initially providing IFN- based treatment. 
In late 2016, a UNITAID- funded prospective cohort study 
evaluating IFN- free HCV regimens with DAAs was initi-
ated in the clinic. Within the MSF- Dawei clinic, there 
were 73 local staff members and 2 expatriate staff. Data 
including patient characteristics, outcomes and costs 
were collected from this UNITAID study, which was part 
of a larger multicentre cohort study to evaluate the effec-
tiveness and cost- effectiveness of HCV screening and 
treatment programmes in LMICs.17
We assessed costs and outcome data among chronically 
HCV- infected (HCV RNA- positive) patients from the 
MSF- Dawei HIV cohort initiated on IFN- free DAA treat-
ment between November 2016 and October 2017. There 
were no restrictions on treatment eligibility by HCV 
disease stage or substance use criteria. Prior to initiation, 
patients underwent liver disease staging and testing for 
comorbidities. Patients were classified by METAVIR stage 
(F0, F1, F2, F3, F4) based on transient elastography with 
those classified as having cirrhosis (F4) if they had a liver 
stiffness measure of ≥11 kPa. Decompensated cirrhosis 
(DC) was defined as liver stiffness ≥11 kPa and Child- 
Pugh score ≥6 based on values for HCV/HIV- coinfected 
patients.18 All patients were screened for hepatocellular 
carcinoma (HCC) via abdominal ultrasound. Patients 
were treated with sofosbuvir+daclatasvir (SOF+DAC) 
without or with ribavirin (RBV) as per the 2015 Euro-
pean Association for the Study of the Liver recommen-
dations.19 During treatment, patients returned every 
2–4 weeks (or more frequently, if necessary) for routine 
clinical monitoring and biological testing (figure 1). 
Patients were evaluated for sustained virological response 
(SVR), defined as a negative HCV RNA test 12 or more 
Figure 1 Treatment protocols for the MSF full model of 
care and simplified model of care for patients on a 12- week 
treatment regimen. Mandatory appointments shown, optional 
appointments excluded. ALT, alanine aminotransferase; AST, 
aspartate aminotransferase; HBsAg, hepatitis B surface 
antigen; HCV, hepatitis C virus; INR, international normalised 
ratio (coagulation test); MSF, Médecins Sans Frontières; TSH, 
thyroid stimulating hormone.
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weeks after the end of treatment. Patients who did not 
achieve SVR12 with DAAs were not retreated. Patients 
were considered as lost to follow- up if they did not return 
within 2 months after a scheduled appointment and were 
not noted as dead or transferred out. Intention- to- treat 
SVR rates were calculated that included patients who 
were lost to follow- up or died.
Costing methods
Overall costing approach
We performed a patient- level microcosting analysis of 
HCV treatment delivery from a programme provider’s 
perspective, incremental to the standard twice- yearly HIV 
visits. Data on costs were obtained from MSF’s financial 
records, receipts and price lists from a 12- month period 
(January 2017–December 2017), when the majority of 
the HCV- related costs were incurred. Records prior to 
2017 were used to allocate a proportion of capital equip-
ment costs obtained in previous years based on expected 
service lives estimated by interviewing local staff. Using 
an ingredients approach, patient- level resource use 
(in terms of type and frequency of visit) was combined 
with cost information for each patient interaction type. 
Patient- level data on number and type of visits, clinical 
examinations, laboratory investigations, treatment regi-
mens and treatment outcomes were extracted from elec-
tronic medical records.20 Resources were valued from 
MSF financial records, invoices, price lists and addition-
ally informed through interviews with key staff (finance, 
logistics, pharmacy manager, medical activity manager). 
We present costs stratified by HCV- related visit compo-
nents, HCV- related lab costs, DAA costs and coordination 
costs, as described below. Results are presented in 2017 
US$.
HCV-related visit components
HCV- related visits were classified as: (1) pre- treatment 
(2) on- treatment and (3) post- treatment as per the 
MSF protocol (figure 1). All HCV- related labs costs 
were excluded from visit costs and costed separately 
(see below). Each HCV visit included personnel time 
specific to the visit (patient- interacting and administra-
tive time, determined by staff diaries), space/materials 
depending on which area of the clinic was used (labo-
ratory, medical, counselling, pharmacy), and proportion 
of usage for HCV treatment. For each location, the visit 
cost incorporated recurrent costs (general personnel 
costs, medicines (excluding HCV), medical and labora-
tory supplies, non- medical supplies, transport operating 
costs, building rental and insurance, maintenance, utili-
ties and bills, freight and clearance, travel and training) 
and capital costs (buildings, vehicles, medical equipment 
including FibroScan transient elastography machine, 
laboratory equipment including GeneXpert real- time 
PCR system, cold chain equipment, non- medical equip-
ment, construction and rehabilitation, and furniture). 
Building space for each location visit was determined 
through site maps and visual inspection and allocated as 
HCV related by determining the proportion of all consul-
tations which were HCV related from records. Personnel 
effort by visit type was determined by general staff cate-
gory (coordination, nursing, medical doctor, individual 
counselling, pharmacy, registration, human resources, 
support staff), involvement in HCV- related activities and 
allocated to proportion of staff, budget, floor space or 
consultations. Group counselling for HCV treatment, in 
which patients shared HCV treatment experiences and 
served as a discussion group for treatment preparation 
(including counselling on HCV infection, transmission, 
encouragement for family testing, lifestyle, treatment 
and monitoring plan, and contact tracing to minimise 
loss to follow- up), was costed separately.
HCV-related laboratory costs
Costs of HCV- related laboratory investigations as per the 
MSF protocol (figure 1) were obtained from invoices and 
price lists.
DAA costs
Unit costs were determined from MSF invoices (online 
supplemental table S1). Patient- specific DAA costs were 
calculated based on observed length of treatment and 
treatment regimen.
Coordination costs
Per visit MSF coordination costs were included from the 
local coordination site (Dawei) and country coordination 
(Yangon) using a top- down method (see online supple-
mental material). For Dawei, HCV- related coordination 
costs were estimated through obtaining the remaining 
personnel, recurrent and capital costs associated with the 
HCV programme, after extracting specific costs attribut-
able to direct HCV visits by type. For Yangon, coordina-
tion costs included the proportion of personnel effort 
attributed to the Dawei programme by staff type and non- 
personnel costs (eg, all HCV- related activities) and were 
allocated as a proportion of the total budget.
Cost-effectiveness methods
Disease progression model
We developed a compartmental, deterministic Markov 
model of liver disease progression in a closed cohort 
of diagnosed HCV/HIV- coinfected adults (figure 2), 
based on the liver disease distribution in the MSF cohort 
(online supplemental table S1). We simulated disease 
progression through each stage of HCV- related hepatic 
fibrosis (METAVIR stages F0, F1, F2, F3), compensated 
cirrhosis (CC, METAVIR F4), DC and HCC. Liver- related 
mortality was assumed to only occur from DC or HCC. 
The model did not include liver transplantation, as this 
is not commonly performed in Myanmar. The model 
was additionally stratified by treatment history and 
outcome (untreated, treated and cured, or treated and 
failed). Individuals with F3 or milder liver disease who 
were treated and achieved SVR were assumed not to have 
further liver fibrosis progression. Those with CC, DC or 
HCC who were treated and achieved SVR could progress 
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to more severe liver disease states or liver- related death 
but at reduced rates. We assumed those who achieved 
SVR cannot be reinfected and those who did not achieve 
SVR with DAAs were not retreated. The model was devel-
oped in Matlab R2018a.
Disease progression rates and mortality
Liver disease state transition probabilities (online supple-
mental table S3) were based on previous studies among 
HCV/HIV- coinfected individuals which suggest faster 
acceleration to more advanced hepatic fibrosis stages 
and mortality among HCV/HIV- coinfected individuals 
off antiretroviral therapy (ART) compared with HCV/
HIV- coinfected individuals on ART.1 21–26 Background 
(non- HCV related) mortality rates were estimated given 
the CD4 count distribution, ART status of the cohort 
and estimated life expectancy based on mean age of the 
cohort weighted by sex27 (This information references 
1.3 Background (non- HCV related) mortality rate calcu-
lation in the online supplemental text).
Costs
HCV treatment and routine HIV care and treatment 
costs were obtained through our patient- level analyses. 
Due to a lack of information available on patient access 
to care for advanced liver disease associated with HCV 
outside of the HIV clinic, for the baseline analysis we use 
estimates of HCV- related disease management costs from 
similar income settings (Cambodia), adjusted for Gross 
Domestic Product (GDP; online supplemental table S3). 
Patients who achieved SVR were assumed to remain in 
their disease stage and continue to accrue disease stage 
costs despite being cured.
Health utilities
Health outcomes were evaluated in disability- adjusted 
life- years (DALYs). Health disutilities for HIV and liver 
disease stages were obtained from the Global Burden of 
Disease (online supplemental table S3)28 and coinfec-
tion disutility values calculated as: [1−(1−HIV disability 
weight)×(1−HCV disability weight)].26
Cost-effectiveness analyses
We evaluated the cost- effectiveness of HCV treatment 
for HCV/HIV- infected individuals compared with no 
HCV treatment. We evaluated the following treatment 
protocol scenarios:
 ► ‘Observed MSF’: data from observed full MSF 
protocol from the implemented UNITAID HCV DAA 
study in 2016/2017, using 2017 DAA prices.
 ► ‘MSF updated DAA cost’: costs estimated from full 
MSF protocol, but with updated DAA prices based 
on the outcomes of the MSF HCV tender for quality- 
assured generic DAAs (reduces 12- weeks SOF+DCV 
from US$493 to US$120) negotiated after the study 
in 2018.
 ► ‘Simplified MoH’: we estimate costs of a simpli-
fied treatment protocol (as proposed by MSF to the 
Myanmar MoH after the study in 2018, figure 1) if 
implemented by the MoH. The simplified protocol 
reduced the number of visits and laboratory meas-
urements and incorporated partial task- shifting from 
doctors to nurses. To represent implementation by the 
MoH, we also use local staff costs (26% less expensive 
than current staff costs), no MSF coordination costs, 
quality- assured generic DAA prices and updated HCV 
test costs (previously OraQuick rapid test, and now 
SD Bioline HCV rapid test resulting in a~US$5 reduc-
tion per test). We simulate cost- effectiveness of the 
proposed simplified protocol assuming the same SVR 
as observed with the full protocol.
The model was run for 100 years, with cost and utilities 
discounted at 3%/year. To account for parameter uncer-
tainty, we performed a probabilistic sensitivity analysis, 
sampling 1000 parameter sets from parameter distribu-
tions (online supplemental table S3). We calculated the 
mean incremental cost- effectiveness ratio (ICER, mean 
incremental costs divided by mean incremental DALYs 
averted) for the intervention compared with no treat-
ment. Interventions with an ICER less than a willingness- 
to- pay (WTP) threshold of one times per capita GDP 
of Myanmar (US$1250 in 2017) were considered cost- 
effective.29 30
One-way sensitivity analyses
We performed several one- way sensitivity analyses on the 
ICER for each of the ‘Observed MSF’, ‘MSF updated 
DAA cost’ and ‘Simplified MoH’ strategies compared 
with no treatment. We varied the discount rate (0% and 
6% compared with 3% at baseline), time horizon (20 and 
50 years vs 100 years at baseline), SVR rate (90% and 98% 
vs 96% at baseline), initial distribution of fibrosis stage 
Figure 2 Schematic of Markov model showing (A) untreated 
chronic HCV disease progression by liver disease states and 
(B) stratification of the model by treatment. For those who 
are cured (achieve SVR), further liver disease progression 
is halted (if in stages F0–F3) or reduced compared with 
those who do not achieve SVR (if in stages CC, DC, HCC). 
F0–F3 are METAVIR hepatic fibrosis scores determined by 
transient elastography (<11.0 kPa); cirrhosis: METAVIR score 
≥11.0 kPa; DC: METAVIR score ≥11.0 kPa and Child- Pugh 
score ≥6. HCC was determined by abdominal ultrasound. 
CC, compensated cirrhosis; DC, decompensated cirrhosis; 
HCC, hepatocellular carcinoma; HCV, hepatitis C virus; SVR, 
sustained virological response.
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(30% and 60% patients with cirrhosis vs 46% at baseline), 
HCV/HIV coinfection disutility values (lower and upper 
bounds vs mean values at baseline), transient elastography 
costs (cost in Cambodia observed with higher volume 
of use compared with Dawei: $4 compared with $115), 
reinfection among those who achieved SVR (5%/year vs 
0% at baseline), no cost for care for all hepatic fibrosis 
stages (vs F0: $0; F1: $35; F2: $80; F3: $137; F4: $207; DC: 
$314; HCC: $378 at baseline), no coordination cost (vs 
$98 for patients without cirrhosis and $142 for patients 
with cirrhosis at baseline), and accelerated liver disease 
progression among patients with genotype (GT) 3 (HR: 
1.31 for cirrhosis (95% CI 1.22 to 1.39); HR: 1.80 for HCC 
(95% CI 1.61 to 2.03)31 ; among 56% of patients). Addi-
tionally, for the ‘Simplified MoH’ strategy, we examine 
task- shifting to nurse- led care only during treatment, 
reducing overall physician interactions by 56% (nine 
visits vs four; and nurse interaction by 66% from six inter-
actions to two) and examine equal SVR rates as observed 
in the MSF trial or those reduced to SVR rates to 70% in 
the event the simplified model results in reduced SVR.
HCV screening and treatment sensitivity analyses
Because screening occurred several years prior to the 
UNITAID intervention, our base case evaluates the cost- 
effectiveness of the DAA treatment programme only. For 
a sensitivity analysis, we explored the cost- effectiveness of 
a combined screening and treatment programme for the 
‘Simplified MoH’ scenario compared with no screening 
and treatment across various HCV seroprevalences 
(0.5%–10%), reflecting likely geographical heteroge-
neity across Myanmar (see online supplemental informa-
tion for details). We estimated associated screening costs 
based on testing yields for each prevalence scenario, 
assuming HCV antibody testing using the SD Bioline 
HCV rapid test (US$2.33) and GeneXpert HCV RNA test 
(US$21.09) with staff costs included.
Patient and public involvement
Study participants and the public were not involved in the 
design, conduct or reporting of this study. However, study 
findings will be disseminated through publications and 
presentations at conferences and other public events.
RESULTS
Treatment outcomes
From November 2016 to October 2017, all 122 HIV- 
infected patients (mean age 43 years) who screened 
positive for HCV were treated with DAAs (56/122 (46%) 
with cirrhosis (CC or DC)). No HCC was detected among 
those treated or untreated. Roughly half of the treated 
cohort were GT3 (51%), followed by GT1 (46%) and 
GT6 (3%). Of these, 96% (n=117) achieved SVR. The 
majority of patients with cirrhosis (n=50; 89%) were 
treated with 24 weeks of SOF+DAC, but six were treated 
with 12 weeks of SOF+DAC+RBV resulting in lower costs 
(all six patients achieved SVR; GT1: n=1; GT3: n=4; GT6: 
n=1). One patient was previously treated with IFN- based 
HCV treatment (peg- IFN+RBV) prior to the availability 
of IFN- free DAA therapy and retreated with DAAs once 
available. Of those who did not achieve SVR (n=5), 
one died, one did not complete treatment and three 
completed treatment. There was no difference in SVR by 
liver fibrosis stage (online supplemental table S2).
Treatment delivery cost
The average cost of HCV treatment per patient was $1229 
(95% CI $848 to $1829) for patients without cirrhosis 
and $1971 (95% CI $1307 to $2686) for patients with 
cirrhosis (online supplemental figure S1). Variations 
in cost were predominantly due to differences in dura-
tions of treatment and drug regimens, with minor differ-
ences in monitoring. DAA drug cost was the largest cost 
component and main driver of difference in cost by liver 
disease stage (without cirrhosis: $524 vs with cirrhosis: 
$1122; table 1). The second largest driver of cost was 
laboratory costs, with minimal difference by liver disease 
stage (without cirrhosis: $421 vs with cirrhosis: $437). 
Of these laboratory costs, transient elastography costs 
comprised $115, which was high because of the initial 
purchase price (~US$49 037) and relatively low usage 
(159 measurements in 2017). Visit costs were the third 
largest contributor to cost (breakdown by visit type in 
online supplemental table S4). Within the personnel 
component of visit costs, 61% of the personnel costs 
were due to physician costs (three local, one foreign), 
as the protocol incorporated physician- led treatment. 
Coordination costs were on average $98 per treatment 
for patients without cirrhosis and $142 per treatment for 
patients with cirrhosis (45% from Dawei, and 55% from 
Yangon; This corresponds to 1.1 Valuation of coordina-
tion costs in the online supplemental text).
Updated quality- assured generic DAA costs were 
obtained after the end of our study ($120 for 12 weeks of 
SOF/DAC before MSF- overhead charges (online supple-
mental table S1). With these updated costs, the total esti-
mated DAA costs when incorporating RBV (included in 
54% of treatments) were $184 for 12 weeks, $453 for 24 
weeks, reflecting variations in dose). With these costs, 
based on the observed treatment protocol, the total 
cost per treatment would be $889 for patients without 
cirrhosis and $1302 for patients with cirrhosis (table 1). 
In this scenario, the highest contributors to overall cost 
would be the laboratory and monitoring costs.
Cost-effectiveness of HCV treatment among HIV-infected 
individuals
The ‘Observed MSF’ treatment programme (mean treat-
ment costs: $1229 (patients without cirrhosis), $1971 
(patients with cirrhosis)) resulted in an average incre-
mental cost of $2121 per patient treated including annual 
HIV care costs (online supplemental table S5), and 3.35 
DALYs averted per patient. This led to a mean ICER of 
$634/DALY averted compared with no treatment, cost- 
effective compared with a WTP threshold of one times 
the per capita GDP of Myanmar ($1250) (table 2). In 
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this analysis, 100% of the simulations fell under the WTP 
threshold.
The ‘MSF updated DAA cost’ analysis (with updated 
DAA prices, mean treatment cost $889 (patients without 
cirrhosis), $1302 (patients with cirrhosis)) produced a 
mean ICER of $488/DALY averted compared with no 
treatment, cost- effective under the WTP threshold (all 
simulations fell under the WTP threshold).
Finally, a ‘Simplified MoH’ strategy (also with cheaper 
drugs) could result in substantial reductions in treat-
ment cost (patients without cirrhosis: $417, patients 
with cirrhosis: $601), and if resulting in equal treatment 
outcomes, could be highly cost- effective (mean ICER 
$316 DALY averted compared with no treatment, all 
simulations fell under the WTP threshold).
One-way sensitivity analyses
The ‘Observed MSF’ treatment programme remained 
cost- effective across all scenarios, if the discount rate was 
reduced to 0% or increased to 6%, there were no costs of 
care for hepatic fibrosis stages, coordination costs were 
excluded, GT3 patients were assumed to have acceler-
ated liver disease progression, transient elastography 
costs were decreased, there was a time horizon of 20 or 
50 years, they achieved a reduced SVR rate, there was 
different disutility estimates used, cirrhosis prevalence 
varied or reinfection rate was 5%/year (figure 3).
The ‘MSF updated DAA cost’ and ‘Simplified MoH’ 
scenarios remained cost- effective for all sensitivity analyses 
(online supplemental figures S2 and S3). Furthermore, 
the ‘Simplified MoH’ scenario remained cost- effective 
with SVR rates of 70% (ICER: $372).
Screening and treatment sensitivity analyses
A combined screening and treatment programme among 
HIV- infected individuals implemented by the MoH using 
the ‘Simplified MoH’ strategy could be cost- effective 
at all HCV seroprevalences considered examined, 
including the lowest prevalence (0.5%; ICER: $489), 
below the national monoinfection estimate (2.7%) and 
Figure 3 Sensitivity analysis of the cost- effectiveness of 
the ‘Observed MSF’ model of care with 2017 DAA costs 
compared with no treatment. Costs shown in US$. The 
reduced FibroScan cost (US$3.89) scenario reflects the 
FibroScan cost estimated in similar income country setting 
with higher volume (GDP adjusted cost from Cambodia, 
US$2017; $4.31). Dark and light blue bars displayed when 
two values of a parameter were examined and resulted 
in ICER values lower and above the baseline ICER value 
(US$634). DAA, direct- acting antiviral therapy; GDP, Gross 
Domestic Product; ICER, incremental cost- effectiveness 
ratio; MSF, Médecins sans Frontières; SVR, sustained 
virological response (at 12 weeks).
Table 2 Incremental cost- effectiveness of HCV treatment among HIV- infected individuals in Myanmar compared with no 
treatment, as observed and with proposed simplified protocols and newly negotiated DAA costs
Strategy
Cost (US$ 2017) per capita DALYs per capita ICER mean
Total mean (95% CI)
Incremental mean 
compared with no 
treatment (95% CI) Total mean (95% CI)
Incremental mean 
compared with no 
treatment (95% CI)
$/DALY averted 
compared with no 
treatment
No treatment 3991.71 (3133.86 to 
4955.87)





6112.72 (5019.45 to 
7170.54)
2121.01 (1885.59 to 
2214.67)





5624.94 (4550.21 to 
6738.39)
1633.23 (1416.35 to 
1782.52)




5050.30 (4009.81 to 
6128.90)
1058.59 (875.95 to 
1173.03)
18.54 (17.48 to 19.50) −3.35 (−3.29 to −3.42) 316.23
Estimates for interventions include cost of annual HIV care and treatment.
*‘Observed MSF intervention’ presents summary data from observational study, including 2017 DAA prices.
†‘MSF with updated DAA costs’ estimates costs with updated DAA prices for quality- assured generic DAAs negotiated in 2018.
‡‘Simplified MoH’ strategy estimates costs with generic DAAs and a proposed simplified protocol (figure 1), with local staff costs and 
no overheads.
DAA, direct- acting antiviral; DALYs, disability- adjusted life- years; HCV, hepatitis C virus; ICER, incremental cost- effectiveness ratio; 
MoH, Ministry of Health; MSF, Médecins sans Frontières.
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the 8% observed among HIV- infected individuals in 
Dawei (ICER: $334; online supplemental figure S4).6 
The ‘Simplified MoH’ strategy was cost- effective for 
HCV seroprevalences above 0.1% (ICER: $1152 at 0.1%; 
online supplemental figure S4).
DISCUSSION
Main findings
Our study found that the DAA treatment programme 
among HCV/HIV- coinfected patients in Myanmar imple-
mented by MSF is cost- effective, particularly with quality- 
assured generic DAAs. Moreover, a simplified model of 
care (proposed by MSF to the Myanmar MoH, incorpo-
rating fewer visits and task- shifting) implemented by the 
MoH with local staff could be highly cost- effective (ICER 
<$400/DALY averted compared with no treatment), if 
not associated with worse treatment outcomes, and could 
be cost- effective if combined with an HCV screening 
programme among HIV- infected individuals. These 
findings hold even with lower than observed (90%) SVR 
rates and reinfection rate was 5% per year. With quality- 
assured generic DAAs, treatment remained cost- effective 
even over 20- year time horizons.
The majority of treatment costs in our study were 
comprised of DAA costs in 2017, which were negotiated 
to lower prices after the study period in 2018 by the 
MSF Supply Centers and MSF Access campaign ($120 
for 12- week course),16 underscoring the importance of 
generic competition to reduce drug prices and improve 
access to HCV treatment. The cost of transient elastog-
raphy also contributed markedly to cost of treatment 
delivery because of the high purchase price and low 
annual use. These costs could be reduced if used in a 
higher volume clinic or if non- invasive methods for deter-
mining hepatic fibrosis were used (eg, Fibrosis-4 Index 
for Hepatic Fibrosis, aspartate aminotransferase- to- 
platelet ratio index or FibroSure).
Comparisons with existing literature
To our knowledge, our study is the first to evaluate the 
real- world costs and cost- effectiveness of DAA treatment 
in an implemented HCV treatment programme among 
HIV- infected individuals in a clinical setting in an LMIC. 
However, our study supports previous analyses indi-
cating that HCV treatment is likely cost- effective in LMIC 
settings where DAAs are available at low costs. One study 
in Egypt found that implementing an HCV screening 
programme with IFN- based DAA therapy compared with 
no screening would be cost- effective.11 Compared with 
IFN- based therapy, IFN- free DAA therapy is superior in 
efficacy, has shorter treatment duration and better toler-
ability,32–35 yet in many settings historically more costly, 
though costs continue to fall.36 37 Similarly, two cost- 
effectiveness studies in India showed that implementing 
HCV screening and treatment with generic DAAs would 
be cost- saving within about a decade, but these studies 
did not use programmatic treatment delivery or outcome 
data.12 38 Importantly, none of these studies, ours 
included, incorporated data on access to healthcare, 
which may be low in LMICs, and therefore it is possible 
that treatment is less cost- effective than estimated if fewer 
medical costs are associated with untreated HCV infec-
tion. While our sensitivity analyses indicated that HCV 
treatment remained cost- effective with no cost of care for 
hepatic fibrosis stages, further work is warranted to assess 
real- world medical utilisation for liver disease in LMICs.
Strengths and limitations
The main strength of our study is that it was based on 
real- world programmatic costs and outcome data. 
However, as with all modelling studies, there were 
numerous uncertainties in the parameter values. Never-
theless, we incorporated these uncertainties in our anal-
ysis, conducted sensitivity analyses, and our results were 
generally robust to most of these uncertainties. First, no 
patients in our cohort received additional care for HCV 
within the MSF- Dawei HIV clinic, but it was unknown 
whether they received care at other medical facilities and 
so was not included in our analysis. Future work in this 
area is warranted to refine our estimates.
Second, we used published data on disease progres-
sion from other settings, while it is unclear whether 
these are truly generalisable to Myanmar. Our baseline 
analysis did not simulate differential disease progression 
by GT. Half our cohort was GT3, which has been associ-
ated with accelerated liver disease progression in HCV- 
monoinfected individuals,31 39 40 yet it is unclear if this is 
true in HCV/HIV coinfection. A sensitivity analysis incor-
porating accelerated disease progression among GT3 
patients improved the cost- effectiveness.
Third, reinfection rates among HIV- infected individ-
uals in Myanmar are unknown, however we note that our 
analyses with quality- assured generic DAA prices indi-
cated that treatment was cost- effective even with reinfec-
tion rates of 5%.
Fourth, although we used observational data for our 
main analysis (‘Observed MSF’), our analyses examining 
a simplified model of care as proposed by MSF to the 
MoH are theoretical. The MoH strategy assumed equal 
SVR rates and projected costs based on adherence to the 
planned visits and monitoring plan. The true cost of an 
MoH strategy is unknown and could be different between 
HCV treatment programmes implemented at the hospital 
versus clinic level, due to variation in staff and clinical 
monitoring costs. Real- world data on costs and treat-
ment outcomes are required to confirm these findings, 
although our sensitivity analyses show that treatment 
with generic DAA costs was cost- effective when including 
lower SVR and higher treatment costs, indicating that it 
is likely that our results would hold in other settings with 
worse treatment outcomes. Furthermore, compared with 
no treatment, treatment with DAAs would likely remain 
cost- effective in other real- world settings even with lower 
SVR rates. Additionally, the MoH may be able to acquire 
DAAs at even lower prices than the updated DAA costs 
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included in our analyses, if purchased in bulk, which 
would further increase cost- effectiveness.
Fifth, the Markov model that we developed to describe 
HCV disease progression simulated an average popula-
tion behaviour and thus did not incorporate individual- 
level heterogeneity. Sixth, both the study and model did 
not account for retreatment after DAA failure as retreat-
ment was not available during the study period and is 
currently not recommended by national guidelines. We 
note however that within the MSF cohort, select individ-
uals have been eligible for retreatment since 2019.
Finally, our study was based on data from a cohort 
receiving care from an MSF clinic in a single, rural setting 
(Dawei, Myanmar), so it is unclear whether our results are 
generalisable to the country or if scaled up to the broader 
population of people living with HIV. Additionally, our 
treated cohort were all on ART with well- controlled HIV 
and had access to consistent HIV counselling which may 
have resulted in greater adherence levels and follow- up 
than in a larger healthcare system without available coun-
selling. Integrating HCV treatment into existing ART 
programmes and HIV clinics may be an effective strategy 
to reach HCV/HIV- coinfected populations and should 
be considered. Additionally, we recognise the clinical 
and medical environments equivalent to that of MSF 
clinics, which offer intensive follow- up protocols and 
patient engagement, may not exist nationally. Non- MSF 
clinics in Myanmar may differ in resource allocation and 
availability such as human resources, logistics and supply 
chains, which may influence (1) access and support for 
patients seeking care and treatment, and (2) treatment 
adherence, patient retention and patient outcomes, 
which could impact cost- effectiveness.
CONCLUSION
In conclusion, we found the MSF treatment programme 
for HCV infection among HIV- infected individuals in 
Myanmar cost- effective, with the potential of being even 
more cost- effective when using a simplified protocol as 
long as this does not result in worse treatment outcomes. 
Access to affordable, quality- assured generic DAAs 
improved cost- effectiveness.
Practical implications
Given our cost- effectiveness projections, national 
programmes in Myanmar and similar settings should no 
longer consider DAA cost a barrier, but rather consider 
these data along with simplified models of care as a means 
to cure people with HCV infection and progress towards 
WHO HCV elimination goals. While this study evaluated 
the current HCV treatment programme implemented 
by MSF, these results can be informative to the MoH in 
Myanmar and other similar LMIC settings.
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